SCHEMBL24253808

SCHEMBL24253808

O=C1CCCC2(CCN(c3ncnc(N4CCC(O)(C(F)(F)F)CC4)n3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.32

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.32
MLYCD O95822 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
SCN9A Q15858 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A3 Q01959 1/20 0.31
PIK3CA P42336 2/20 0.30
MTOR P42345 2/20 0.30
LRRK2 Q5S007 1/20 0.30
CYP11B2 P19099 1/20 0.30
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253936 0.84 PIK3CA (0.31) HTR1ADRD2ADRA1DADRA1AADRA1B
SCHEMBL30424409 0.84 PIK3CA (0.31) HTR1ADRD2ADRA1DADRA1AADRA1B
SCHEMBL24253620 0.81 MLYCD (0.32) MLYCDHTR1ADRD2ADRA1DADRA1A
SCHEMBL24253726 0.81 DPP4 (0.36) DPP4SCN9ACYP11B2
SCHEMBL30423561 0.81 DPP4 (0.36) DPP4SCN9ACYP11B2
SCHEMBL30423566 0.79 HCRTR1 (0.32) HTR1ADRD2ADRA1DADRA1AADRA1B
SCHEMBL24253933 0.79 HCRTR1 (0.32) HTR1ADRD2ADRA1DADRA1AADRA1B
SCHEMBL30423985 0.76 HCRTR1 (0.35) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253866 0.76 HCRTR1 (0.35) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253624 0.75 ELOVL1 (0.37) DPP4HTR1ADRD2ADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP claimed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN claimed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 DPP4 582/4885MLYCD 4658/4885HTR1A 1336/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 DPP4 582/4885MLYCD 4658/4885HTR1A 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.